142 related articles for article (PubMed ID: 16822276)
1. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
[TBL] [Abstract][Full Text] [Related]
2. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
[TBL] [Abstract][Full Text] [Related]
3. Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide.
Jakate AS; Roy P; Patel A; Abramowitz W; Persiani S; Wangsa J; Kapil R
Br J Clin Pharmacol; 2005 Nov; 60(5):498-507. PubMed ID: 16236040
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
5. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
6. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Malhotra B; Dickins M; Alvey C; Jumadilova Z; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):263-9. PubMed ID: 21545485
[TBL] [Abstract][Full Text] [Related]
7. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
8. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.
Moller RA; Fisher JM; Taylor AE; Kolluri S; Gardner MJ; Obach RS; Walsky RL
Ann Pharmacother; 2006 Jan; 40(1):32-7. PubMed ID: 16368922
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
10. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.
Lehtinen T; Tolonen A; Turpeinen M; Uusitalo J; Vuorinen J; Lammintausta R; Pelkonen O; Scheinin M
Biopharm Drug Dispos; 2013 Oct; 34(7):387-95. PubMed ID: 23852652
[TBL] [Abstract][Full Text] [Related]
11. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
12. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.
Yasui-Furukori N; Saito M; Inoue Y; Niioka T; Sato Y; Tsuchimine S; Kaneko S
Eur J Clin Pharmacol; 2007 Jan; 63(1):51-6. PubMed ID: 17124578
[TBL] [Abstract][Full Text] [Related]
13. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.
Böhmer GM; Drollmann A; Gleiter CH; Nave R
Clin Pharmacokinet; 2008; 47(5):343-9. PubMed ID: 18399715
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
[TBL] [Abstract][Full Text] [Related]
16. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women.
Gardner M; Taylor A; Wei G; Calcagni A; Duncan B; Milton A
J Clin Pharmacol; 2006 Jan; 46(1):52-8. PubMed ID: 16397284
[TBL] [Abstract][Full Text] [Related]
18. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
19. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
20. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
